The Digital and Quantitative Medicine (DQM) group at Biogen is a multi-disciplinary group of physicians and scientists whose purpose is to provide Biogen with methods for the quantification of the health state of patients and provide a rigorous paradigm for improving clinical trial outcomes. DQM applies a physician-scientist model to incorporate multi-scale computational modelling and simulation to bring specific value to development and discovery, catalyzing the organization towards a human-centric transformative quantitative biology strategy for drug development/discovery. DQM includes platforms in clinical technologies (including digital and internet of things approaches), quantitative medicine and experimental medicine and relies on robust interfaces with groups across Biogen.
Main tasks in the project
Biogen will contribute to the project mainly by providing data from the Watch-PD study, A multicentre, prospective, longitudinal digital assessment study of Parkinson’s Disease progression in early PD patients.
In addition, we will support the WP7 in the efforts toward a library of models for observations of digital endpoints.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.